China Universal Asset Management Co., Ltd. Relmada Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 21, 2022	BUY	$18.3 - $37.02 $5,160 - $10,439	282 New	282 $10,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

Franklin Resources Inc San Mateo, CA

1.3M
Shares

$3.59 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.26M
Shares

$3.47 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.19M
Shares

$3.27 Million
0.01% of portfolio
Parsons Capital Management Inc

1M
Shares

$2.77 Million
0.21% of portfolio
Palo Alto Investors LP Palo Alto, CA

732K
Shares

$2.02 Million
0.33% of portfolio

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $79M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account